It’s happened to all of us: you find the perfect model for your needs — a bracket, a box, a cable clip, but it only comes in STL, and doesn’t quite fit. That problem will never happen if you’re using ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

What’s the best way to bring your AI agent ideas to life: a sleek, no-code platform or the raw power of a programming language? It’s a question that sparks debate among developers, entrepreneurs, and ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

Abstract: Many recent image restoration methods use Transformer as the backbone network and redesign the Transformer blocks. Differently, we explore the parameter-sharing mechanism over Transformer ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Once the Season ends, the weapon will become a part of the random drop rewards pool, allowing you to obtain it randomly again or for the first time. Modified Heatsink Battery Battery slowly recharges ...

Jake Fillery is an Evergreen Editor for Game Rant who has been writing lists, guides, and reviews since 2022. With thousands of engaging articles and guides, Jake loves conversations surrounding all ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027. Recursion ...